Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits

References

• Abe BT, Shin DS, Mocholi E, et al. NFAT1 supports tumor-induced energy of CD4(+) T cells. Cancer Res. 2012;72:4642–4651.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413–1428.
   PubMed Web of Science ®Google Scholar
• Wei SC, Anang NAAS, Sharma R, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019;116:22699–22709.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226ra32.
   PubMed Web of Science ®Google Scholar
• Morello S, Capone M, Sorrentino C, et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017;15:244.
   PubMed Web of Science ®Google Scholar
• Deinlein T, Wolf IH, Rainer B, et al. Treatment of primary and metastatic multifocal mucosal melanoma of the oral cavity with imatinib. Case Rep Oncol. 2017;10:558–563.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–1737.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210–2221.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Amatruda T, Nemunaitis J, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMed. 2019;47:89–97.
   PubMed Web of Science ®Google Scholar
• Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer. 2019;145:974–978.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhou H, Ni C, et al. Immunotherapy in pancreatic cancer: new hope or mission impossible?. Cancer Lett. 2019;445:57–64.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Binder A, Brody JD. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol. 2015;9:1966–1981.
   PubMed Web of Science ®Google Scholar
• Mi Y, Smith CC, Yang F, et al. A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy. Adv Mater Weinheim. 2018;30:e1706098.
   PubMed Web of Science ®Google Scholar
• Singh M, Khong H, Dai Z, et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014;193:4722–4731.
   PubMed Web of Science ®Google Scholar
• Fakhari A, Nugent S, Elvecrog J, et al. Thermosensitive gel-based formulation for intratumoral delivery of toll-like receptor 7/8 dual agonist, MEDI9197. J Pharm Sci. 2017;106:2037–2045.
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28:4324–4332.
   PubMed Web of Science ®Google Scholar
• Wang S, Campos J, Gallotta M, et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E7240–E7249.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Czerwinski DK, Levy S, et al. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018;10:eaan4488.
   PubMed Web of Science ®Google Scholar
• Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011;32:5134–5147.
   PubMed Web of Science ®Google Scholar
• Hewakuruppu YL, Dombrovsky LA, Chen C, et al. Plasmonic "pump-probe" method to study semi-transparent nanofluids. Appl Opt. 2013;52:6041–6050.
   PubMed Web of Science ®Google Scholar
• Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015;88:20150207.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Elahi-Gedwillo KY, Carlson M, Zettervall J, et al. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79:372–386.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Int J Pharm. 2017;523:203–216.
   PubMed Web of Science ®Google Scholar
• Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep. 2013;46:131–138.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254–258.
   PubMed Web of Science ®Google Scholar
• Kong L, Zhou Y, Bu H, et al. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res. 2016;35:131.
   PubMed Web of Science ®Google Scholar
• Bicho A, Peça IN, Roque ACA, et al. Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int J Pharm. 2010;399:80–86.
   PubMed Web of Science ®Google Scholar
• Horwitz DA, Bickerton S, Koss M, et al. Suppression of murine lupus by CD4+ and CD8+ Treg cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor β. Arthritis Rheumatol. 2019;71:632–640.
   PubMed Web of Science ®Google Scholar
• Schmid D, Park CG, Hartl CA, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8:1747.
   PubMed Web of Science ®Google Scholar
• Sacchetti C, Rapini N, Magrini A, et al. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem. 2013;24:852–858.
   PubMed Web of Science ®Google Scholar
• Ou W, Thapa RK, Jiang L, et al. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release. 2018;281:84–96.
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Rosalia RA, Kleinovink JW, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release. 2014;192:209–218.
   PubMed Web of Science ®Google Scholar
• Rosalia RA, Cruz LJ, van Duikeren S, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015;40:88–97.
   PubMed Web of Science ®Google Scholar
• Raghuwanshi D, Mishra V, Suresh MR, et al. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine. 2012;30:7292–7299.
   PubMed Web of Science ®Google Scholar
• Hu G, Guo M, Xu J, et al. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Front Immunol. 2019;10:1998.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hardie J, Zhang X, et al. Effects of engineered nanoparticles on the innate immune system. Semin Immunol. 2017;34:25–32.
   PubMed Web of Science ®Google Scholar
• Oh WK, Kim S, Choi M, et al. Cellular uptake, cytotoxicity, and innate immune response of silica-titania hollow nanoparticles based on size and surface functionality. ACS Nano. 2010;4:5301–5313.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhang Y, Xin Y, et al. Interactions between nanoparticles and dendritic cells: from the perspective of cancer immunotherapy. Front Oncol. 2018;8:404.
   PubMed Web of Science ®Google Scholar
• Shima F, Akagi T, Akashi M. Effect of hydrophobic side chains in the induction of immune responses by nanoparticle adjuvants consisting of amphiphilic poly(γ-glutamic acid). Bioconjug Chem. 2015;26:890–898.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Goldsmith M, Solfiell DJ, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134:3965–3967.
   PubMed Web of Science ®Google Scholar
• Oh JY, Kim HS, Palanikumar L, et al. Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nat Commun. 2018;9:4548.
   PubMed Web of Science ®Google Scholar
• Saha K, Rahimi M, Yazdani M, et al. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona. ACS Nano. 2016;10:4421–4430.
   PubMed Web of Science ®Google Scholar
• Settanni G, Zhou J, Suo T, et al. Protein corona composition of poly(ethylene glycol)- and poly(phosphoester)-coated nanoparticles correlates strongly with the amino acid composition of the protein surface. Nanoscale. 2017;9:2138–2144.
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, et al. Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerf. 2000;18:301–313.
   PubMed Web of Science ®Google Scholar
• Xiao W, Lin J, Li M, et al. Prolonged in vivo circulation time by zwitterionic modification of magnetite nanoparticles for blood pool contrast agents. Contrast Media Mol Imaging. 2012;7:320–327.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Liu Y, Ayaz F, et al. Immunomodulatory effects of coated gold nanoparticles in LPS-stimulated in vitro and in vivo murine model systems. Chem. 2016;1:320–327.
   PubMed Web of Science ®Google Scholar
• Kato Y, Ozawa S, Miyamoto C, et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13:89.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang Y, Li Z, et al. "Sweet" architecture-dependent uptake of glycocalyx-mimicking nanoparticles based on biodegradable aliphatic polyesters by macrophages. J Am Chem Soc. 2017;139:14684–14692.
   PubMed Web of Science ®Google Scholar
• Morris ZS, Guy EI, Werner LR, et al. Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites. Cancer Immunol Res. 2018;6:825–834.
   PubMed Web of Science ®Google Scholar
• Iyoda T, Yamasaki S, Kawamura M, et al. Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells. Cancer Sci. 2019;110:875–887.
   PubMed Web of Science ®Google Scholar
• Jain S, Tran TH, Amiji M. Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials. 2015;61:162–177.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin YX, Qiao SL, et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017;112:153–163.
   PubMed Web of Science ®Google Scholar
• Mahon OR, Browe DC, Gonzalez-Fernandez T, et al. Nano-particle mediated M2 macrophage polarization enhances bone formation and MSC osteogenesis in an IL-10 dependent manner. Biomaterials. 2020;239:119833.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
   PubMed Web of Science ®Google Scholar
• Amidi M, de Raad M, Crommelin DJ, et al. Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine. Syst Synth Biol. 2011;5:21–31.
   PubMedGoogle Scholar
• Kanaoka E, Takahashi K, Yoshikawa T, et al. A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol. 2001;53:295–302.
   PubMed Web of Science ®Google Scholar
• Kanaoka E, Takahashi K, Yoshikawa T, et al. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm. 2003;29:1149–1153.
   PubMed Web of Science ®Google Scholar
• Anderson PM, et al. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother. 1992;12:19–31.
   PubMed Web of Science ®Google Scholar
• Sethuraman SN, Singh MP, Patil G, et al. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity. Theranostics. 2020;10:3397–3412.
   PubMed Web of Science ®Google Scholar
• Meraz IM, Savage DJ, Segura-Ibarra V, et al. Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer. Mol Pharm. 2014;11:3484–3491.
   PubMedGoogle Scholar
• Francian A, Namen S, Stanley M, et al. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. Nanomedicine. 2019;18:326–335.
   PubMed Web of Science ®Google Scholar
• Nomura T, Koreeda N, Yamashita F, et al. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res. 1998;15:128–132.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res. 2000;6:2528–2537.
   PubMed Web of Science ®Google Scholar
• Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem. 2017;86:541–566.
   PubMed Web of Science ®Google Scholar
• Koshy ST, Cheung AS, Gu L, et al. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv Biosyst. 2017;1:1600013.
   PubMed Web of Science ®Google Scholar
• Liu Y, Crowe WN, Wang L, et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat Commun. 2019;10:5108.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Engle X, Scarlett UK, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest. 2009;119:2231–2244.
   PubMed Web of Science ®Google Scholar
• He W, Liang P, Guo G, et al. Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep. 2016;6:24506.
   PubMed Web of Science ®Google Scholar
• Nikitczuk KP, Schloss RS, Yarmush ML, et al. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival. J Cancer Ther. 2013;4:280–290.
   PubMedGoogle Scholar
• Da Silva CG, Camps MGM, Li TMWY, et al. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles. Theranostics. 2019;9:6485–6500.
   PubMed Web of Science ®Google Scholar
• Min Y, Roche KC, Tian S, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017;12:877–882.
   PubMed Web of Science ®Google Scholar
• Han HD, Byeon Y, Jang JH, et al. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep. 2016;6:38348.
   PubMed Web of Science ®Google Scholar
• Li X, Min M, Du N, et al. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol. 2013; 2013:387023.
   PubMedGoogle Scholar
• Zaharoff DA, Rogers CJ, Hance KW, et al. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007;25:2085–2094.
   PubMed Web of Science ®Google Scholar
• Tahamtan A, Barati M, Tabarraei A, et al. Antitumor immunity induced by genetic immunization with chitosan nanoparticle formulated adjuvanted for HPV-16 E7 DNA vaccine. Iran J Immunol. 2018;15:269–280.
   PubMed Web of Science ®Google Scholar
• Kim TH, Jin H, Kim HW, et al. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther. 2006;5:1723–1732.
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Hance KW, Rogers CJ, et al. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother. 2010;33:697–705.
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Hoffman BS, Hooper HB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res. 2009;69:6192–6199.
   PubMed Web of Science ®Google Scholar
• Guo L, Yan DD, Yang D, et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano. 2014;8:5670–5681.
   PubMed Web of Science ®Google Scholar
• Fogli S, Montis C, Paccosi S, et al. Inorganic nanoparticles as potential regulators of immune response in dendritic cells. Nanomedicine (Lond). 2017;12:1647–1660.
   PubMed Web of Science ®Google Scholar
• Tsai YS, Chen YH, Cheng PC, et al. TGF-β1 conjugated to gold nanoparticles results in protein conformational changes and attenuates the biological function. Small. 2013;9:2119–2128.
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Ochyl LJ, et al. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9:1074.
   PubMed Web of Science ®Google Scholar
• Cha BG, Jeong JH, Kim J. Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy. ACS Cent Sci. 2018;4:484–492.
   PubMed Web of Science ®Google Scholar
• Hong X, Zhong X, Du G, et al. The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency. Sci Adv. 2020;6:eaaz4462.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu J, Zhang Y, et al. The toxicity of silica nanoparticles to the immune system. Nanomedicine (Lond). 2018;13:1939–1962.
   PubMed Web of Science ®Google Scholar
• An M, Yu C, Xi J, et al. Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale. 2018;10:9311–9319.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen H, Wang H, et al. A synergistic cancer immunotherapy nano-system for preventing tumor growth. Chem Eng J. 2020;380:122472.
   Web of Science ®Google Scholar
• Chen Q, Xu L, Liang C, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193.
   PubMed Web of Science ®Google Scholar
• Chen PM, Pan WY, Wu CY, et al. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials. 2020;230:119629.
   PubMed Web of Science ®Google Scholar
• Mühlberger M, Janko C, Unterweger H, et al. Functionalization of T lymphocytes with citrate-coated superparamagnetic iron oxide nanoparticles for magnetically controlled immune therapy. Int J Nanomed. 2019;14:8421–8432.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tang J, Abbaraju PL, et al. Hybrid nanoreactors: enabling an off-the-shelf strategy for concurrently enhanced chemo-immunotherapy. Angew Chem Int Ed Engl. 2018;57:11764–11769.
   PubMed Web of Science ®Google Scholar
• Zhang N, Song J, Liu Y, et al. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. J Control Release. 2019;306:15–28.
   PubMed Web of Science ®Google Scholar
• Lu S, Neoh KG, Huang C, et al. Polyacrylamide hybrid nanogels for targeted cancer chemotherapy via co-delivery of gold nanoparticles and MTX. J Colloid Interf Sci. 2013;412:46–55.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang C, Zhang X, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019;14:89–97.
   PubMed Web of Science ®Google Scholar
• Hoopes PJ, Wagner RJ, Duval K, et al. Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation. Mol Pharm. 2018;15:3717–3722.
   PubMed Web of Science ®Google Scholar
• Ito A, Tanaka K, Honda H, et al. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng. 2003;96:364–369.
   PubMed Web of Science ®Google Scholar
• Chen W, Qin M, Chen X, et al. Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al2O3 nanoparticles. Theranostics. 2018;8:2229–2241.
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Bookstaver ML, Sweeney EE, et al. Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma. Biomater Sci. 2019;7:1875–1887.
   PubMed Web of Science ®Google Scholar
• Ito A, Matsuoka F, Honda H, et al. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother. 2004;53:26–32.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu F, Men K, et al. Modified Fe3O4 magnetic nanoparticle delivery of CpG inhibits tumor growth and spontaneous pulmonary metastases to enhance immunotherapy. Nanoscale Res Lett. 2018;13:240.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Sheen MR, Zhang P, et al. Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine. 2014;10:1273–1285.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang B, Zai W, et al. Perfluorocarbon nanoparticle-mediated platelet inhibition promotes intratumoral infiltration of T cells and boosts immunotherapy. Proc Natl Acad Sci U S A. 2019;116:11972–11977.
   PubMed Web of Science ®Google Scholar
• Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine. 2010;6:634–641.
   PubMed Web of Science ®Google Scholar
• Miermont A, Barnhill H, Strable E, et al. Cowpea mosaic virus capsid: a promising carrier for the development of carbohydrate based antitumor vaccines. Chemistry. 2008;14:4939–4947.
   PubMed Web of Science ®Google Scholar
• Wang C, Beiss V, Steinmetz NF. Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties. J Virol. 2019;93:e00129-19.
   PubMed Web of Science ®Google Scholar
• Murray AA, Wang C, Fiering S, et al. In situ vaccination with cowpea vs tobacco mosaic virus against melanoma. Mol Pharm. 2018;15:3700–3716.
   PubMedGoogle Scholar
• Lizotte PH, Wen AM, Sheen MR, et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2016;11:295–303.
   PubMed Web of Science ®Google Scholar
• Kerstetter-Fogle A, et al. Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy. Cancers (Basel). 2019;11:515.
   Web of Science ®Google Scholar
• Wang C, Steinmetz NF. CD47 blockade and cowpea mosaic virus nanoparticle in situ vaccination triggers phagocytosis and tumor killing. Adv Healthc Mater. 2019;8:e1801288.
   PubMed Web of Science ®Google Scholar
• Czapar AE, Tiu BDB, Veliz FA, et al. Slow-release formulation of cowpea mosaic virus for in situ vaccine delivery to treat ovarian cancer. Adv Sci (Weinh). 2018;5:1700991–1700991.
   PubMedGoogle Scholar
• Shukla S, Wang C, Beiss V, et al. Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer. ACS Nano . 2020;14:2994–3003.
   PubMed Web of Science ®Google Scholar
• Lee KL, Murray AA, Le DHT, et al. Combination of plant virus nanoparticle-based in situ vaccination with chemotherapy potentiates antitumor response. Nano Lett. 2017;17:4019–4028.
   PubMed Web of Science ®Google Scholar
• Lebel MÈ, Chartrand K, Tarrab E, et al. Potentiating cancer immunotherapy using papaya mosaic virus-derived nanoparticles. Nano Lett. 2016;16:1826–1832.
   PubMed Web of Science ®Google Scholar
• Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. Mol Pharm. 2011;8:29–43.
   PubMedGoogle Scholar
• Farley MM, Hu B, Margolin W, et al. Minicells, back in fashion. J Bacteriol. 2016;198:1186–1195.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell. 2007;11:431–445.
   PubMed Web of Science ®Google Scholar
• Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13:605–619.
   PubMed Web of Science ®Google Scholar
• Jivrajani M, Nivsarkar M. Ligand-targeted bacterial minicells: futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells. Nanomedicine. 2016;12:2485–2498.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ji W, He L, et al. E. coli nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy. Theranostics. 2018;8:1690–1705.
   PubMed Web of Science ®Google Scholar
• Tsuji S, Chen X, Hancock B, et al. Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer. Mol Ther Oncolytics. 2016;3:16004–16004.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Langova V, Bailey D, et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One. 2016;11:e0151832.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Madrid-Weiss J, Amaro-Mugridge NB, et al. Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle. 2007;6:2099–2105.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Desai J, Rosenthal M, et al. A first-time-in-human phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS One. 2015;10:e0144559.
   PubMed Web of Science ®Google Scholar
• Carleton HA, Lara-Tejero M, Liu X, et al. Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery. Nat Commun. 2013;4:1590–1590.
   PubMed Web of Science ®Google Scholar
• Hancock BM, McGuire KL, Tsuji S, et al. A single intravesical instillation of VAX014 inhibits orthotopic superficial bladder tumor implantation to increase survival. Anticancer Res. 2016;36:6243–6248.
   PubMed Web of Science ®Google Scholar
• Karagiannis ED, Anderson DG. Minicells overcome tumor drug-resistance. Nat Biotechnol. 2009;27:620–621.
   PubMed Web of Science ®Google Scholar
• Singh MP, Sethuraman SN, Ritchey J, et al. In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. Int J Hyperthermia. 2019;36:64–73.
   PubMed Web of Science ®Google Scholar
• Beg S, Kawish SM, Panda SK, et al. Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines. Semin Cancer Biol. 2019.
   Web of Science ®Google Scholar
• Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018;292:256–276.
   PubMed Web of Science ®Google Scholar
• Young JK, Figueroa ER, Drezek RA. Tunable nanostructures as photothermal theranostic agents. Ann Biomed Eng. 2012;40:438–459.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Chen C. Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Adv Mater Weinheim. 2013;25:3869–3880.
   PubMed Web of Science ®Google Scholar
• Zhou F, Li X, Naylor MF, et al. InCVAX-a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett. 2015;359:169–177.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Nie X, et al. Near infrared laser-induced targeted cancer therapy using thermoresponsive polymer encapsulated gold nanorods. J Am Chem Soc. 2014;136:7317–7326.
   PubMed Web of Science ®Google Scholar
• Wang C, Xu L, Liang C, et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater Weinheim. 2014;26:8154–8162.
   PubMed Web of Science ®Google Scholar
• Bear AS, Kennedy LC, Young JK, et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PloS One. 2013;8:e69073.
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Burga RA, Sweeney EE, et al. Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine. 2017;13:771–781.
   PubMed Web of Science ®Google Scholar
• Duval KEA, Vernice NA, Wagner RJ, et al. Immunogenetic effects of low dose (CEM43 30) magnetic nanoparticle hyperthermia and radiation in melanoma cells. Int J Hyperthermia. 2019;36:37–46.
   PubMed Web of Science ®Google Scholar
• Ito A, Shinkai M, Honda H, et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother. 2003;52:80–88.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ito A, Kobayashi T, et al. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer. 2005;116:624–633.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kakimi K, Nakayama E, et al. Antitumor immunity by magnetic nanoparticle-mediated hyperthermia. Nanomedicine (Lond)). 2014;9:1715–1726.
   PubMed Web of Science ®Google Scholar
• Oei AL, Korangath P, Mulka K, et al. Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. Int J Hyperthermia. 2019;36:47–63.
   PubMed Web of Science ®Google Scholar
• Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Controlled Release. 2012;158:487–494.
   PubMed Web of Science ®Google Scholar
• Ektate K, Munteanu MC, Ashar H, et al. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci Rep. 2018;8:13062.
   PubMed Web of Science ®Google Scholar
• VanOsdol J, Ektate K, Ramasamy S, et al. Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer. J Control Release. 2017;247:55–63.
   PubMed Web of Science ®Google Scholar
• Skalina KA, Singh S, Chavez CG, et al. Low intensity focused ultrasound (LOFU)-mediated acoustic immune priming and ablative radiation therapy for in situ tumor vaccines. Sci Rep. 2019;9:15516.
   PubMed Web of Science ®Google Scholar
• Silvestrini MT, Ingham ES, Mahakian LM, et al. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight. 2017;2:e90521.
   PubMed Web of Science ®Google Scholar
• Eranki A, Farr N, Partanen A, et al. Boiling histotripsy lesion characterization on a clinical magnetic resonance imaging-guided high intensity focused ultrasound system. PloS ONE. 2017;12:e0173867.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Namai E, Oda Y, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release. 2010;142:245–250.
   PubMed Web of Science ®Google Scholar
• Chen YL, Wang CY, Yang FY, et al. Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model. Cell Death Dis. 2014;5:e1178.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086.
   PubMed Web of Science ®Google Scholar
• Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev. 2017;114:33–42.
   PubMed Web of Science ®Google Scholar
• Barrueto L, Caminero F, Cash L, et al. Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol. 2020;13:100738.
   PubMed Web of Science ®Google Scholar
• Ajina R, Zahavi DJ, Zhang YW, et al. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Semin Cancer Biol. 2019;65:28–37.
   PubMed Web of Science ®Google Scholar
• Gong J, Hendifar A, Tuli R, et al. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018;7:32.
   PubMed Web of Science ®Google Scholar
• Fay AP, Antonarakis ES. Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. Ann Transl Med. 2019;7:S7.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhu C, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12:7647–7662.
   PubMed Web of Science ®Google Scholar
• Tselikas L, de Baere T, Isoardo T, et al. Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies. J Immunother Cancer. 2020;8:e000579.
   PubMed Web of Science ®Google Scholar